This guideline considers issues associated with the processing of renewals in the centralised procedure, with an aim of giving procedural guidance to marketing authorisation holders (MAHs). It has been developed by the CHMP following consultation of the interested parties and the European Commission Services.
Guideline on the processing of renewals in the centralised procedure: document with tracked changes
Draft: consultation closedConsultation dates:
to
Reference Number: EMEA/CHMP/2990/00 Rev.5Summary:
In order for a marketing authorisation to remain valid, a renewal is required five years after the granting of the marketing authorisation (irrespective of whether the marketing authorisation is suspended). This guideline considers issues associated with the processing of renewals in the centralised procedure to provide procedural guidance to marketing-authorisation holders. It has been developed by the Committee for Medicinal Products for Human Use following consultation of interested parties and European Commission services.
Overview of external comments received, and European Medicines Agency / Committee for Medicinal Products for Human Use feedback / action on each comment on guideline on the processing of renewals in the centralised proced...
Overview of comments received on draft guideline on criteria for requiring one additional five-year renewal for centrally authorised medicinal products (EMEA/131973/2006)